mometasone-furoate and Erythema

We wanted to confirm the benefit of mometasone furoate (MF) in preventing acute radiation reactions, as shown in a previous study (Boström et al, Radiother Oncol 2001;59:257-265).. The study was a double-blind comparison of MF with D (Diprobase), administered daily from the start of radiation therapy for 5 weeks in patients receiving breast radiation therapy, 40 Gy in 2.67-Gy fractions daily over 3 weeks. The primary endpoint was mean modified Radiation Therapy Oncology Group (RTOG) score.. Mean RTOG scores were significantly less for MF than for D (P=.046). Maximum RTOG and mean erythema scores were significantly less for MF than for D (P=.018 and P=.012, respectively). The Dermatology Life Quality Index (DLQI) score was significantly less for MF than for D at weeks 4 and 5 when corrected for Hospital Anxiety and Depression (HAD) questionnaire scores.. MF cream significantly reduces radiation dermatitis when applied to the breast during and after radiation therapy. For the first time, we have shown a significantly beneficial effect on quality of life using a validated instrument (DLQI), for a topical steroid cream. We believe that application of this cream should be the standard of care where radiation dermatitis is expected.

Topics: Administration, Topical; Breast Neoplasms; Dermatologic Agents; Dose Fractionation, Radiation; Double-Blind Method; Drug Administration Schedule; Emollients; Erythema; Female; Humans; Middle Aged; Mometasone Furoate; Pregnadienediols; Radiodermatitis; Sample Size; Skin Cream

Considerable interobserver variability exists among providers and between providers and patients when measuring subjective symptoms. In the recently published Phase III N06C4 trial of mometasone cream vs. placebo to prevent radiation dermatitis, the primary provider-assessed (PA) endpoint, using the Common Toxicity Criteria for Adverse Events (CTCAE), was negative. However, prospectively planned secondary analyses of patient-reported outcomes (PROs), using the Skindex-16 and Skin Toxicity Assessment Tool (STAT), were positive. This study assesses the relationship between PA outcomes and PROs.. Pearson correlation coefficients were calculated to compare the three tools. Statistical correlations were defined as follows: <0.5, mild; 0.5-0.7, moderate; and >0.7, strong.. CTCAE dermatitis moderately correlated with STAT erythema, and CTCAE pruritus strongly correlated with STAT itching. CTCAE pruritus had a moderate correlation with Skindex-16 itching. Comparing the 2 PRO tools, Skindex-16 itching correlated moderately with STAT itching. Skindex-16 burning, hurting, irritation, and persistence all showed the strongest correlation with STAT burning; they showed moderate correlations with STAT itching and tenderness.. The PRO Skindex-16 correlated well with the PRO portions of STAT, but neither tool correlated well with CTCAE. PROs delineated a wider spectrum of toxicity than PA measures and provided more information on rash, redness, pruritus, and annoyance measures compared with CTCAE findings of rash and pruritus. PROs may provide a more complete measure of patient experience than single-symptom, PA endpoints in clinical trials assessing radiation skin toxicity.

Topics: Breast Neoplasms; Communication; Dermatologic Agents; Erythema; Female; Humans; Mometasone Furoate; Outcome Assessment, Health Care; Pregnadienediols; Prospective Studies; Pruritus; Quality of Life; Radiodermatitis; Treatment Outcome

The aim of this study was to evaluate the ability of topical tacrolimus 0.1% under occlusion for 48 h to suppress nickel-elicited allergic contact dermatitis in a randomized, petrolatum- and mometasone furoate 0.1% ointment-controlled double-blind, intra-individual study which included 28 women volunteers. 3 closed patch tests (Finn Chambers on Scanpor, Epitest Ltd Oy, Tuusula, Finland) containing 0.1 ml of 5% nickel sulfate in petrolatum were applied on day 0. After removal on day 2, the study compounds were applied under occlusion for 48 h. The eczema reaction and the degree of erythema were evaluated clinically and by reflectance spectrophotometry at days 4 and 7, respectively. Mean visual scores corresponding to petrolatum-treated sites were significantly higher than those corresponding to both mometasone furoate and tacrolimus at days 4 (P < 0.001) and 7 (P < 0.001). In both tacrolimus- and mometasone furoate-treated sites, there was a significant decrease in visual scores with time (P < 0.001) from day 2 to day 7, and the corresponding mean decreases in scores were 0.73 and 1.04, respectively. The difference between both was 0.30 in favour of tacrolimus (95% confidence intervals, -0.04 and 0.65), although this did not reach statistical significance (P = 0.084). Mean erythema index values were similar at day 2. Significant differences among treatment sites were seen at days 4 (P < 0.001) and 7 (P < 0.001). The decrease was significantly more pronounced on day 7 in patches where tacrolimus had been supplied (P < 0.5). This method might provide useful means to compare different concentrations and/or presentations of tacrolimus or other calcineurin inhibitors and topical anti-inflammatory agents.

Topics: Administration, Topical; Adult; Anti-Allergic Agents; Dermatitis, Allergic Contact; Dose-Response Relationship, Drug; Double-Blind Method; Emollients; Erythema; Female; Humans; Immunosuppressive Agents; Irritants; Middle Aged; Mometasone Furoate; Nickel; Ointments; Patch Tests; Petrolatum; Pregnadienediols; Spectrophotometry; Tacrolimus; Time Factors

The therapy for skin diseases with topical glucocorticoids is limited by their local and systemic side effects. A glucocorticoid with an improved benefit-to-risk ratio is desirable.. A new topical corticoid, methylprednisolone aceponate (MPA) 0.1% ointment, was compared with the same formulation of mometasone furoate.. The two ointments were compared with respect to suppression of UVB light-induced erythema (n = 20) and with respect to atrophogenicity and appearance of telangiectasia (n = 20) in two double-blind trials with intraindividual comparisons in healthy volunteers. In a third trial, serum cortisol levels were measured in volunteers receiving extensive (60% of body surface) cutaneous application of MPA (n = 10) or mometasone furoate (n = 11).. MPA and mometasone furoate were equally effective in suppressing UVB light-induced erythema. Atrophogenicity, as well as the incidence and severity of telangiectasia, were significantly more pronounced with mometasone furoate than with MPA. Both ointments decreased serum cortisol levels and did not differ significantly in this respect. However, the incidence of serum cortisol level suppression was higher in the mometasone furoate group than in the MPA group.. MPA ointment has equal antiinflammatory activity and similar cortisol suppression but significantly fewer local side effects than mometasone furoate.

Topics: Administration, Topical; Adolescent; Adrenal Insufficiency; Adult; Anti-Inflammatory Agents; Double-Blind Method; Erythema; Female; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Mometasone Furoate; Ointments; Pregnadienediols; Radiation Injuries; Telangiectasis; Ultraviolet Rays

Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Erythema; Female; Humans; Mometasone Furoate; Skin; Skin Diseases, Genetic; Skin Pigmentation; Treatment Outcome; Ultraviolet Therapy; Vitiligo

Topics: Administration, Topical; Adolescent; Anti-Inflammatory Agents; Anticoagulants; Betacoronavirus; Chilblains; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Erythema; Female; Gels; Heparin; Humans; Mometasone Furoate; Ointments; Pandemics; Pneumonia, Viral; SARS-CoV-2

Serpentine erythematous or hyperpigmented streaks along the superficial venous network proximal to the site of injection may occur as a distinctive eruption after infusion of several chemotherapeutic agents. This morphological pattern has been described under various terms like, "persistent supravenous erythematous eruption," "persistent serpentine supravenous hyperpigmented eruption," or "persistent serpentine supravenous hyperpigmentation." These changes belong to the same clinical spectrum, which most often starts as erythematous serpentine streaks precisely located over the injected veins; the erythema is shortly replaced by hyperpigmentation. We report here a case of docetaxel-induced supravenous serpentine dermatitis with some interesting clinical and histological features.

Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Eruptions; Erythema; Female; Forearm; Humans; Hyperpigmentation; Injections, Intravenous; Middle Aged; Mometasone Furoate; Pregnadienediols; Pruritus; Taxoids; Veins

Dactinomycin (AMD) is an effective drug in the management of several malignant disorders and has been used for almost 40 years. Skin and subcutaneous toxicities following extravasation are well known and can be harmful. Similarly radiation-recall is a well established phenomenon following the administration of AMD. We report a patient who developed a localized brawny erythema in the crural folds and the axillae, likely due to AMD. This rare skin complication of AMD seems to benefit from topical corticosteroid treatment, although postinflammatory hyperpigmentation may take months to disappear.

Topics: Administration, Cutaneous; Adolescent; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Dactinomycin; Drug Eruptions; Erythema; Female; Glucocorticoids; Humans; Hyperpigmentation; Kidney Neoplasms; Mometasone Furoate; Pregnadienediols; Wilms Tumor

The bioactivity of a novel topical glucocorticosteroid, mometasone furoate 0.1% fatty cream was compared with betamethasone dipropionate 0.05% cream and betametasone valerate 0.1% cream. An ultraviolet light (UV-B)-induced inflammation assay in humans was used, and the combined effect of a single, open application of the corticosteroids was evaluated. Reduction of UV-B induced inflammation was monitored by laser Doppler blood flowmetry, clinical skin scoring and skin reflectance spectrophotometry. Skin scoring and reflectance spectrophotometry were found unsuitable because one of the cream vehicles contained titanium dioxide which shielded skin erythema. Laser Doppler blood flowmetry showed that mometasone furoate 0.1% fatty cream was more than twofold better in reducing UV-B-induced inflammation than betamethasone dipropionate 0.05% cream and betametasone valerate 0.1% cream, and that the effect was sustained for at least 24 h after a single application.

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Betamethasone Valerate; Erythema; Glucocorticoids; Humans; Laser-Doppler Flowmetry; Middle Aged; Mometasone Furoate; Ointments; Pharmaceutical Vehicles; Pregnadienediols; Regional Blood Flow; Skin; Ultraviolet Rays